US buys $26M worth of hard-to-get monkeypox treatment

As the U.S. creeps toward 10,000 monkeypox cases, the HHS ordered $26 million worth of Tpoxx IV fluid, a monkeypox treatment that’s difficult for physicians to order, according to an Aug. 9 press release. 

Advertisement

Tpoxx isn’t fully authorized to treat monkeypox, but the CDC named it an “investigational drug” Aug. 3, which allowed physicians to prescribe the treatment but only after they signed up for the clinical trial and filled out each patient’s forms, which some said takes three to four hours.

In an Aug. 3 article, FDA officials reaffirmed their decision to wait on authorizing Tpoxx for monkeypox, which is available in pill and IV fluid form, reasoning that it’s only been tested in animals. 

A supplier of the fluid option, New York City-based Siga Technologies, plans to deliver the shipment in 2023.

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Pharmacy

Advertisement

Comments are closed.